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Cardiac cell transplantation offers new opportunities as apotent therapeutic tool to improve left ventricular (LV)function and reverse postinfarction remodeling in isch-emic heart disease. Skeletal myoblasts (SKMBs) en-
graft within infarcted myocardium, form myotubes, induce angio-
genesis, and improve both diastolic and systolic LV function.1
Bone marrow–derived mononuclear cells (BM-MNCs) likewise
engraft, increase angiogenesis, and improve myocardial perfu-
sion.2 Both cell types have moved to clinical testing, and preclin-
ical studies suggest that they could have synergistic functional
benefits that argue for combined transplantation.3,4 Intramyocar-
dial injections are currently performed either percutaneously
through an endoventricular or transvenous approach or surgically
through a thoracotomy or sternotomy. We recently reported a
video-assisted thoracoscopic technique to reduce invasiveness and
perioperative risk of surgical cell delivery that was tested in
uninjured swine hearts.5 In the setting of heart failure (HF), me-
chanical manipulation of the left ventricle both by means of
stabilization and cell injection must be minimized to prevent
hemodynamic compromise, arrhythmia, and ventricular perfora-
tion. Robotically assisted cardiac surgery combines the advantages
of minimal invasiveness and thoracoscopic access but adds a
3-dimensional view and 7 degrees of freedom that requires less
cardiac manipulation than with the 2-dimensional view and limited
freedom of motion of video-assisted thoracoscopic surgery.6 We
therefore propose a robot-assisted, beating-heart cell transplanta-
tion technique for use in severe HF to increase safety, optimize
targeting, and reduce procedural time.
Procedure Description
Eleven injured swine in which HF was previously induced by
means of coronary occlusion and coronary embolism (left anterior
descending coronary ar-
tery, n  9; circumflex
artery, n  2) under-
went robot-assisted cell (n  7) or vehicle (n  4) injection by
using the daVinci robotic system (Intuitive Surgical, Sunnyvale,
Calif). During right single-lung ventilation and antiarrhythmic
prophylaxis (amiodarone, 3 mg/kg; lidocaine, 1 mg/kg), we in-
serted the camera port, 2 instrument ports, and an auxiliary port
(Figure 1, A). After removal of the pericardial fat pad, we incised
the pericardium along the sternal border, dissected pericardial
adhesions, and created a triangular pericardial flap. We inserted the
prefilled injection needle (27-gauge needle attached to 12-inch
tubing; Saf-T E-Z Set, BD, Sandy, Utah) through the auxiliary port
and injected a 7-mL cell suspension containing a combination of
2.9  108  5.9  107 autologous SKMBs and 1.1  108  6.8
 106 autologous BM-MNCs (Figure 1, B) at 6 to 10 sites.
SKMBs were iron oxide labeled, as previously described.5 Viabil-
ity at the time of injection was greater than 85%, and CD56
expression was greater than 80%. BM-MNCs were acutely isolated
from bone marrow aspirate through Ficoll density gradient cen-
trifugation. Injections were performed tangentially to minimize
perforation risk and injectate backflow, covering a target area of 15
to 20 cm2. After cell delivery, the pericardial flap was readapted,
all instrument ports were removed, and the left lung was expanded
under visual control. We inserted a chest tube through the inferior
instrument port, closed the port sites in 3 layers, and flushed the
left thoracic cavity with 0.9% saline (200 mL). After removal of
the chest tube, animals were extubated and recovered according to
postoperative standards. Baseline magnetic resonance imaging
(MRI) was performed 5 weeks after myocardial injury. Follow-up
MRI was repeated at 4 and 7 weeks after cell/vehicle transplantation.
Results
Cell transplantation was completed successfully in 6 of 7 cases.
Intractable ventricular fibrillation occurred in one animal during
cell injection. No conversion to open chest surgery was necessary,
and no other procedure-related complications occurred. Over the
course of the study, single-lung ventilation time was reduced to a
minimum of 23 minutes, and total anesthesia time was reduced to
a minimum of 44 minutes. Cells were successfully transplanted
into the apical, anterior, and lateral target regions of the left
ventricle, including into thinned sections of the scar (target region
wall thickness, 3-14 mm), without ventricular perforation. Postop-
erative MRI studies confirmed retention of iron oxide–labeled cells
in the apex (Figure 2, A) and lateral wall (Figure 2, B) up to 7
weeks after injection. Prussian blue staining of tissue sections
showed engraftment of iron oxide–labeled myotubes in treated
areas (Figure 2, C). Immunofluorescent staining for slow skeletal
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myosin confirmed the skeletal muscle phenotype (Figure 2, D).
Functional data are shown in Table 1.
Discussion
Within the past few years, robot-assisted surgery has revolution-
ized minimally invasive cardiac surgery, allowing complex proce-
dures to be performed on the beating heart. Its major advantages
are increased degrees of freedom, 3-dimensional vision, and mag-
nification of the operating field. Furthermore, it combines mini-
mally invasive access with improved targeting and a decreased risk
of hemodynamic compromise and ventricular perforation, making
it amenable to patients with severely impaired LV function and
remodeling who are not necessarily amenable to endoscopic pro-
cedures. In the present study the robot-assisted technique allowed
controlled cell delivery to the anterior, apical, and lateral regions
of the left ventricle, with minimal requirement for stabilization and
mechanical manipulation. In contrast to current catheter-based
transventricular approaches, safe treatment of target segments with
a wall thickness of less than 5 mm was achievable. Although
efficacy was a secondary end point of the present study, the
improved LV function after cell delivery reinforces the feasibility
of this procedure. A more thorough investigation, including larger
experimental groups, will be necessary to clarify whether the
herein proposed combination of autologous SKMBs and BM-
MNCs is superior to the isolated transplantation of each cell type.
If this is the case, as suggested by other preclinical studies,3,4 our
Table 1. Functional measurements from contrast-enhanced magnetic resonance imaging studies performed 5 weeks after
myocardial injury (baseline) and 4 and 7 weeks after cell or vehicle transplantation
MRI baseline MRI wk 4 MRI wk 7
Cell treated Control P value Cell treated Control P value Cell treated Control P value
EF (%) 33.25 10.14 36.67 4.39 .573 36.75 9.94 33.54 4.57 .639 39.07 5.24 30.1 6.76 .040
RWM (mm) 3.64 1.16 3.75 1.85 .884 6.06 1.60 2.96 1.13 .001 6.40 1.71 4.05 1.57 .029
WTHGN (%) 18.24 14.49 15.05 12.53 .586 21.69 16.64 6.60 5.35 .037 29.69 14.61 8.93 7.87 .020
LVEDV (ml) 193.03 13.61 190.65 11.67 .830 241.1 9.7 244.1 9.1 .698 269.38 12.33 298.23 13.70924 .031
MRI studies were performed with a 1.5-T clinical scanner (Siemens Sonata; Siemens AG, Munich, Germany). Electrocardiography-gated cine MR images
were acquired of the entire cardiac cycle in approximately 16 to 20 phases by using a steady-state free precession pulse sequence in both long- and
short-axis orientations covering the entire left ventricle. Values are expressed as means  standard deviation. Comparisons between cell-treated and
control groups were performed with the unpaired Student t test. MRI, Magnetic resonance imaging; EF, ejection fraction; RWM, regional wall motion;
WTHGN, wall thickening; LVEDV, left ventricular end-diastolic volume.
Figure 1. A, Schematic of robotic cell transplantation using the daVinci surgical robot. Swine are placed in the
supine position and slightly rotated to the right, with elevated shoulders to expand the intercostal spaces. The
camera port (a) is placed in the fifth, instrument ports (b) are placed in the third and seventh, and the auxiliary port
is placed in the sixth (c) intercostal spaces. The 27-gauge winged injection needle (d) is inserted through the
auxiliary port, allowing multiple tangential injections into the target area (shown in purple). B, Intrathoracic view
of the injection device before and during intramyocardial injection. During injection, the rubber wings of the
needle allow safe guidance but minimize the mechanical force applied to the left ventricular wall during slow
injection.
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proposed protocol would offer a streamlined option to provide
patients with HF a combination of autologous SKMBs and BM-
MNCs in one minimally invasive procedure.
In summary, this new method might provide a feasible option
for patients who are currently not eligible for surgical cell trans-
plantation. It combines the benefits of a surgical approach with the
reduction of perioperative risk associated with a minimally inva-
sive procedure. Further investigation is required to clarify whether
the efficacy of robotic cell transplantation equals direct surgical
and catheter-based injection.
We thank experimental surgical services and research animal resources
at the University of Minnesota for diligent and expert assistance in animal
anesthesia and perioperative care.
Figure 2. Upper panels, Contrast-enhanced magnetic resonance cine images showing long-axis views of 2
cell-treated hearts. Cells are visible as signal voids (black dots) in the contrast-enhanced (shown in white) apical
region (A) and the lateral wall (B) of the left ventricle (white arrows). LV, Left ventricle; LA, left atrium. Lower
panels, Corresponding histologic sections of a cell-treated region at low and high magnification. C, Engrafted iron
oxide–labeled myoblasts within the fibrotic infarction scar stain with Prussian blue (black arrows and arrow-
heads). D, Immunofluorescent staining for slow skeletal myosin (shown in green) shows the expression of skeletal
muscle proteins in engrafted cells (white arrows and arrowheads), suggesting cell differentiation. Nuclei within
the section are evidenced by fluorescent blue 4=,6-Diamidino-2-phenylindole (DAPI) staining.
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Percutaneous closure of a ventricular septal defect after surgical
treatment of hypertrophic cardiomyopathy
D. De Wolf, MD, PhD,a Y. Taeymans, MD, PhD,b B. Suys, MD,c D. Matthys, MD, PhD,a and G. Van Nooten, MD, PhD,d
Ghent and Antwerp, Belgium
Surgery or ethanol ablation is indicated in patients withhypertrophic cardiomyopathy who have symptomaticNew York Heart Association (NYHA) class III diseasewith severe left ventricular outflow tract (LVOT) gradi-
ents despite medical treatment.1 A ventricular septal defect (VSD)
after surgical treatment is rare.2 Alternatives for surgical closure
are available in patients with congenital VSDs or post–myocardial
infarction VSDs. Percutaneous closure provides a reasonable al-
ternative.3,4
We describe the technique of percutaneous closure of a VSD
after surgery for hypertrophic cardiomyopathy.5
Clinical Summary
A 50-year-old man was referred for surgery with symptomatic
hypertrophic cardiomyopathy despite medical therapy. He was in
NYHA class III with effort-related angina. Echocardiography
showed asymmetrical left ventricular hypertrophy with a septal
end-diastolic thickness of 19 mm, systolic anterior motion, an
ejection fraction of 66%, and an LVOT gradient of 64 mm Hg.
During catheterization the pressure gradient measured 100 mm Hg.
Ethanol ablation failed. A surgical procedure was performed via a
transaortic approach. By a Morrow septal myomectomy the LVOT
was increased from 16 to 23 mm. However, on control transesoph-
ageal echocardiography the distal part of the LVOT was still
obstructive. This part being out of reach, a second attempt was
made via the left atrium during the same procedure. The antero-
external commissure and the A1 and A2 portions of the anterior
leaflet of the mitral valve were detached from the annulus, and the
myomectomy was completed distally. The anterior leaflet of the
mitral valve was reattached to the annulus. Control echocardiog-
raphy showed total relief of the LVOT obstruction, absence of
mitral regurgitation, but a small muscular VSD. The initial post-
operative course was uneventful. During the following weeks, the
patient’s clinical condition deteriorated, with left and right ven-
tricular failure and mild renal and hepatic failure. On control
echocardiography a muscular VSD 12 mm in diameter with a
left-to-right shunt of 2:1 and half systemic right ventricular pres-
sure was seen. At the right side of the ventricular septum, the VSD
was located near the attachments of the septal leaflet of the
tricuspid valve; at the left side, the distance from the aortic valve
was 18 mm. The thickness of the septum surrounding the VSD
varied between 10 and 14 mm.
On the 20th postoperative day, percutaneous closure of the
VSD was attempted. Under fluoroscopy and transesophageal echo-
cardiographic guidance, the VSD could be crossed via the right
jugular vein and a Mullins transseptal sheath was positioned in the
left ventricle. An Amplatzer 14-mm VSD occluder (AGA Medical
Corporation, Golden Valley, Minn) was delivered in the VSD and
released (Figure 1). The patient had a second-degree atrioventric-
ular block necessitating temporary pacing. Hemodynamic recovery
was immediate, but the postoperative course was complicated by
transient hemolysis and Candida septicemia. One month after
closure of the VSD, the patient could be dismissed. An echocar-
diogram showed a correct position of the VSD device, without any
gradient or residual shunt across the LVOT (Figure 2).
Discussion
A VSD complicating surgery for LVOT obstruction in hypertro-
phic cardiomyopathy is rare.2 These VSDs can be hemodynami-
cally significant. Surgical closure of a VSD can be cumbersome in
a patient who has had recent surgery. Percutaneous or perventricu-
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